Venus Medtech (Hangzhou) Inc. (HKG: 2500) announced the first compassionate use of its VenusP-Valve, a transcatheter pulmonary valve replacement (TPVR) system, at the University of Virginia Advanced Cardiac Valve Center in the United States. This procedure marks a significant milestone for the VenusP-Valve, which is designed to treat patients with moderate to severe pulmonary regurgitation with or without right ventricular outflow tract (RVOT) stenosis.
Clinical Need and Procedure Details
The procedure was performed by Dr. Scott Lim and his team, guided by Professor Feng Yuan from the West China Hospital of Sichuan University and Director Chen Mao online. The patient, a 21-year-old man, had severe pulmonary regurgitation and significant right ventricular, pulmonary artery dilatation, and left ventricular dysfunction following surgical repair of tetralogy of fallot. On the first postoperative day, the patient’s right ventricle was significantly smaller on ultrasonography, with no pulmonary regurgitation, and left ventricular function returned to normal. The patient recovered well and was discharged within 24 hours.
Product Advantages and Market Potential
The VenusP-Valve, with its unique double bell mouth design, offers stable anchoring, simple release, and a wide range of sizes and specifications, meeting the needs of over 85% of patients in clinics. It received approval in Europe in April 2022 and is under review in China, with an expected market launch within this year.-Fineline Info & Tech
